Palisade Bio 的股价飙升了 51.5%，因为溃疡性结肠炎试验结果令人鼓舞，为进一步的研究提供了资金。 Palisade Bio's stock soared 51.5% on promising Ulcerative Colitis trial results, funding further research.

Palisade Bio Inc.的股票在星期四上涨51.5%至2.12美元, Palisade Bio Inc.'s stock rose 51.5% to $2.12 on Thursday, trading 26.97 million shares. 该公司为PALI-2108第一阶段试验、临床前研究以及周转资金出资500万美元,供公众接受。 The company priced a $5 million underwritten public offering to fund the Phase 1 trial of PALI-2108, pre-clinical studies, and working capital. Palisade Bio披露了第一阶段人类对Ultical Colitis的研究的初步结果,很有希望,预计将在2025年上半年报告上线数据。 Palisade Bio revealed promising preliminary results from their Phase 1 human study for Ulcerative Colitis and expects to report topline data in the first half of 2025.